https://www.selleckchem.com/pr....oducts/lenalidomide-
All respiratory care represents some risk of becoming an Aerosol Generating Procedure (AGP) during COVID-19 patient management. Personal Protective Equipment (PPE) and Environmental Control/Engineering is advised. High Velocity Nasal Insufflation (HVNI) and High Flow Nasal Cannula (HFNC) deliver High Flow Oxygen (HFO) therapy, established as a competent means of supporting oxygenation for acute respiratory distress patients, including that precipitated by COVID-19. Although unlikely to present a disproportionate particle disp
Like
Comment
Share
